Preventing relapse of advanced ovarian cancer with PARP inhibitors is now an established strategy. As data from pivotal ...
The median follow-up of 37 months showed that PSMAiSRT improved FFS and eugonadal FFS, with significant improvements in the ...
The FDA has granted fast track designation to the investigational therapeutic agent WTX-124 for the potential treatment of ...
Patients in the no LND arm had shorter surgery duration, less blood loss, and reduced postoperative hospital stay compared to ...
A new study explores strategies to enhance survival rates for patients facing challenges in finding bone marrow donors, advocating for quicker alternative options. Stephanie Lee, MD, MPH, professor ...
Cemiplimab significantly improved disease-free survival in high-risk CSCC, reducing recurrence or death risk by 68% compared ...
The FDA has issued a complete response letter (CRL) to a new drug application (NDA) for Dasynoc for the treatment of chronic ...
Casdatifan activates hundreds of genes in response to low oxygen levels, and when oxygen levels return to normal, HIF-2a is ...
During a live event, Claudine Isaacs, MD, discussed using elacestrant for hormone receptor–positive, HER2-low metastatic ...
Cintredekin besudotox targets IL-12 alpha-2 receptor-expressing tumor cells, using convection-enhanced delivery to bypass the ...
The TROPION-Breast02 trial is the first to show overall survival benefit in this patient population, indicating a potential ...
NBTXR3 combined with radiotherapy and ICIs showed a 47.4% objective response rate and 78.9% disease control rate in melanoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback